【结 构 式】 |
【药物名称】Dexrazoxane, ADR-529, NSC-169780, ICRF-187(HCl) 【化学名称】(+)-(S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione) 【CA登记号】24584-09-6 【 分 子 式 】C11H16N4O4 【 分 子 量 】268.27457 |
【开发单位】Cancer Research UK (Originator) 【药理作用】Cardioprotectants, Chemoprotective Agents, ONCOLYTIC DRUGS, TREATMENT OF POISONING, DRUG ABUSE & DEPENDENCY, DNA Topoisomerase II Inhibitors |
合成路线1
(rac)-1,2-Diaminopropane is resolved using (-)-L-tartaric acid. The bitartrate salt is treated with HCl to give the dihydrochloride salt, (-)-S-1,2-diaminopropane dihydrochloride (I). (I) in water is added to a solution of chloroacetic acid and sodium hydroxide below 20 C, and allowed to stand at room temperature for 7 days. After concentration and filtration, the product is isolated by passing the filtrate down an ion exchange column and eluting with water. The portion of the eluate containing the bulk of the optical activity is concentrated by heating. Crystals of (+)-(S)-1,2-propylene dinitrilotetraacetic acid (II) are obtained by filtration. (II) is heated under nitrogen for 20 h at 165 C to give (+)-(S)-1,2-di(piperazine-2,6-dione)propane.
【1】 NS-2330 enters phase IIb in Alzheimer's disease. J Pharm Sci 1976, 65, 238-242. |
【2】 Eastland, G.; ICRF-187. Drugs Fut 1987, 12, 11, 1017. |